Did you know?
The Capra Science Immunization program™ is optimized for high antibody yields and low background.
Recombinant antibody generation
Our generation of recombinant antibodies (modified, chimeric or humanized) from a monoclonal antibody is provided on a fee-for-service basis. No additional payments from your part, such as milestones, royalties or licence cost. The recombinant antibody will be fully yours, with no strings attached. And we take your confidentiality seriously. Naturally, we are open to signing MTAs or Confidentiality Agreements.
The technology we use has been used for several products which have been clinically evaluated and also approved as therapeutic drugs. Our skilled scientists have more then 20 years of practical experience in many of the critical elements that are a part of the antibody humanization process.
The technology we use has been used for several products which have been clinically evaluated and also approved as therapeutic drugs. Our skilled scientists have more then 20 years of practical experience in many of the critical elements that are a part of the antibody humanization process.
Affinity Guarantee
We leave a generous guarantees for your project; only full payment of the service, providing that the humanized antibody reaches the parameters that defines a successful project. Request a quote to recieve the full details of our quarantee.
Example Of A Project Outline For Antibody Humanization
In short, the humanization of mouse/rat/rabbit monoclonal antibodies by CDR grafting consists of three phases:
Phase I: Sequencing and cloning of VL and VH from hybridoma
Phase II: Advanced In Silico design, with de-immunization
Phase III: In Vitro Validation
Phase I: Sequencing and cloning of VL and VH from hybridoma
Phase II: Advanced In Silico design, with de-immunization
Phase III: In Vitro Validation
Detailed Project Outline
I. Sequencing and cloning of VL and VH from hybridoma
a) RNA preparation from hybridoma cells
b) cDNA synthesis and cloning of VL and VH regions
c) Sequencing of VL and VH
d) Final report of Phase I. containing the antibody sequence
a) RNA preparation from hybridoma cells
b) cDNA synthesis and cloning of VL and VH regions
c) Sequencing of VL and VH
d) Final report of Phase I. containing the antibody sequence
II. Advanced In Silico design, with de-immunization
a) Identify suitable human germlines for humanization by honology studies
b) Generate 3D models of the Fv domains
c) Graft the CDR regions into human Fv framework
d) Evaluation of potentially required back-mutations
e) Screen for potential T-cell epitopes
f) Eliminate potential T-cell epitopes
g) Proposal of up to 5 humanized/de-immunized sequence variants for further in vitro validation
h) Final report of Phase II. containing results of sequence variants.
a) Identify suitable human germlines for humanization by honology studies
b) Generate 3D models of the Fv domains
c) Graft the CDR regions into human Fv framework
d) Evaluation of potentially required back-mutations
e) Screen for potential T-cell epitopes
f) Eliminate potential T-cell epitopes
g) Proposal of up to 5 humanized/de-immunized sequence variants for further in vitro validation
h) Final report of Phase II. containing results of sequence variants.
III. In Vitro validation
a) Small scale preparation of chimeric reference antibody
b) Transfer to binding affinity assay, typically a colorimetric ELISA
c) Gene synthesis and expression vector Construction of 1-5 humanized variants. Your choice of isotype.
d) Small scale preparation of 1-5 humanized antibodies by transient gene expression
e) Assessment of the binding affinity of 1-5 humanized antibodies and the chimeric reference antibody
f) Final report of Phase III. containing results of binding affinities.
g) Deliverables: Purified humanized antibody varians for your evaluation
a) Small scale preparation of chimeric reference antibody
b) Transfer to binding affinity assay, typically a colorimetric ELISA
c) Gene synthesis and expression vector Construction of 1-5 humanized variants. Your choice of isotype.
d) Small scale preparation of 1-5 humanized antibodies by transient gene expression
e) Assessment of the binding affinity of 1-5 humanized antibodies and the chimeric reference antibody
f) Final report of Phase III. containing results of binding affinities.
g) Deliverables: Purified humanized antibody varians for your evaluation
For more details and quotations, please contact us.